RESUMO
Psoriatic patients with latent tuberculosis infection and properly treated active tuberculosis need careful management when prescribing modern biological drugs. Although data and guidelines regarding tumour necrosis factor-α inhibitors advise caution and initiation of prophylactic therapy in patients with latent tuberculosis infection, the same indications do not seem to find equal force for interleukin (IL)-23 and IL-17 inhibitors. In order to evaluate the risk of reactivation in patients with latent tuberculosis infection or properly treated active tuberculosis, an observational retrospective study was conducted on the population referred to our centre at Dermatologic Clinic of University of Turin, Italy. In the last 10 years at the clinic 19 psoriatic patients were found to be at risk of tuberculosis reactivation: 10 patients were QuantiFERON- TB-positive at baseline, 2 became positive during treatment, 6 reported prior tuberculous infection, and 1 was QuantiFERON-TB-negative at baseline and developed disseminated tuberculosis during treatment with anti-tumour necrosis factor-α. Overall, 10.5% of this group of patients developed active tuberculosis; however, stratifying by biologic therapy, zero cases were observed among patients treated with anti-IL-17, -23, or -12/23 over a relatively long follow-up (48.1 months) A review of the available literature following our experience confirms the increased risk of tuberculosis reactivation with tumour necrosis factor-α inhibitors. Concerning anti-IL-23 and IL-17 drugs, available data showed high safety in patients at risk of tuberculosis reactivation. Screening of patients who should be taking IL-17 and IL-23 inhibitors is recommended for public health purposes. In case of a positive result with these therapies, consulting with an infectious diseases specialist is suggested in order to weigh up the risks and benefits of prophylactic treatment.
Assuntos
Tuberculose Latente , Psoríase , Tuberculose , Humanos , Terapia Biológica , Tuberculose Latente/induzido quimicamente , Tuberculose Latente/diagnóstico , Tuberculose Latente/epidemiologia , Necrose , Estudos Observacionais como Assunto , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Estudos Retrospectivos , Centros de Atenção Terciária , Teste Tuberculínico , Tuberculose/prevenção & controle , Fator de Necrose Tumoral alfaAssuntos
Antituberculosos/uso terapêutico , Terapia Biológica/efeitos adversos , Doença de Crohn/tratamento farmacológico , Fístula Intestinal/patologia , Tuberculose Latente/tratamento farmacológico , Tuberculose Gastrointestinal/tratamento farmacológico , Doença de Crohn/complicações , Doença de Crohn/microbiologia , Humanos , Fístula Intestinal/etiologia , Fístula Intestinal/microbiologia , Tuberculose Latente/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Remissão Espontânea , Resultado do Tratamento , Tuberculose Gastrointestinal/induzido quimicamenteRESUMO
Background: Treatment for latent tuberculosis infection (LTBI) is of particular concern in patients with inflammatory bowel disease (IBD) initiating biologic therapies to prevent tuberculosis (TB) reactivation. This study aimed to evaluate the effectiveness of LTBI treatment in IBD patients receiving biologic therapy. Methods: There was a retrospective review of all IBD patients diagnosed with LTBI following a tuberculin skin test (TST) and/or interferon gamma release assay (IGRA) and who received biologic therapy between 2002 and 2016. The primary outcome was tuberculosis reactivation after completion of LTBI treatment. Results: Three-hundred twenty-nine IBD patients were identified, and 35 (27 Crohn's disease; 8 ulcerative colitis) met the study inclusion criteria. The mean age was 38.3 years, and 68.6% were male. The most common LTBI treatment regimen was isoniazid (INH) for 9 months (74%). Biologic therapies used were infliximab (40%), adalimumab (29%), vedolizumab (20%), and certolizumab pegol (11%). Combination therapy with an immunomodulator was administered in 57% of cases. The median time from initiation of LTBI treatment to biologics was 43 days. The mean duration of follow-up was 2.9 years. The estimated median annual risk of TB reactivation without treatment was 0.52% by a prediction formula. Only 1 patient taking adalimumab monotherapy developed reactivation of TB several years after completing 6 months of isoniazid therapy. The estimated TB reactivation rate was 0.98 cases per 100 patient-years of follow-up in our cohort. Conclusions: Treatment for LTBI in patients with IBD treated with biologics is effective but does not eliminate the risk of reactivation. 10.1093/ibd/izy133_video1izy133.video15776720675001.
Assuntos
Antituberculosos/uso terapêutico , Terapia Biológica/efeitos adversos , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Tuberculose Latente/tratamento farmacológico , Mycobacterium tuberculosis/efeitos dos fármacos , Adulto , Feminino , Seguimentos , Fármacos Gastrointestinais/efeitos adversos , Humanos , Testes de Liberação de Interferon-gama , Tuberculose Latente/induzido quimicamente , Tuberculose Latente/diagnóstico , Tuberculose Latente/microbiologia , Masculino , Prognóstico , Estudos Prospectivos , Estudos Retrospectivos , Resultado do Tratamento , Teste TuberculínicoRESUMO
BACKGROUND: Sorafenib is a multikinase inhibitor with an established role in treating renal cell carcinoma and hepatocellular carcinoma. In vivo studies have demonstrated sorafenib's inhibitory effects on various immune cells and cytokines which are essential to the maintenance of latency of granulomas in patients with latent tuberculosis infection. CASE REPORT: A 74-year-old male with clear cell renal cell carcinoma with pulmonary metastases was treated with sorafenib to good effect. However, he developed productive cough, sweats and weight loss. A computed tomography scan of the thorax demonstrated right lower lobe consolidation and cavitation. Sputum analysis was positive for tuberculous smear and culture. A diagnosis of sorafenib-induced tuberculosis reactivation was made. Sorafenib was held and anti-tuberculous antibiotics were commenced, which led to symptomatic and radiographic improvement. CONCLUSION: The authors postulate that sorafenib could increase the risk of progression from latent to active tuberculosis, and urge vigilance and possible screening for latent tuberculosis in patients who are treated with sorafenib.